AR124526A1 - Composiciones farmacéuticas tópicas y métodos - Google Patents
Composiciones farmacéuticas tópicas y métodosInfo
- Publication number
- AR124526A1 AR124526A1 ARP210103688A ARP210103688A AR124526A1 AR 124526 A1 AR124526 A1 AR 124526A1 AR P210103688 A ARP210103688 A AR P210103688A AR P210103688 A ARP210103688 A AR P210103688A AR 124526 A1 AR124526 A1 AR 124526A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- compound
- topical pharmaceutical
- pharmaceutically acceptable
- composition according
- Prior art date
Links
- 239000012049 topical pharmaceutical composition Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 12
- 229940126062 Compound A Drugs 0.000 abstract 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000003963 antioxidant agent Substances 0.000 abstract 3
- 230000003078 antioxidant effect Effects 0.000 abstract 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 abstract 3
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 abstract 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 239000000010 aprotic solvent Substances 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 abstract 1
- 229940055577 oleyl alcohol Drugs 0.000 abstract 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000003961 penetration enhancing agent Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Abstract
La presente divulgación se refiere a una composición farmacéutica tópica que contiene N-[(1S)-1-(5-fluoropirimidin-2-il)etil]-3-(5-isopropoxi-1H-pirazol-3-il)-3H-imidazo[4,5-b]piridin-5-amina (en lo sucesivo también denominada Compuesto A), o una sal farmacéuticamente aceptable del mismo; al uso de la composición farmacéutica tópica como medicamento; a procesos para la preparación de dicha composición farmacéutica tópica; a ciertos métodos nuevos de tratamiento de un trastorno inflamatorio de la piel, particularmente psoriasis, mediante la administración de una composición farmacéutica tópica que contiene el Compuesto A o una sal farmacéuticamente aceptable del mismo; y a nuevas formas cristalinas de una sal mesilato del Compuesto A. Reivindicación 1: Una composición farmacéutica tópica que comprende: a) Compuesto A o una sal farmacéuticamente aceptable del mismo: Compuesto A de fórmula (1); b) al menos un potenciador de la permeación; y c) uno o más excipientes farmacéuticamente aceptables. Reivindicación 5: La composición de acuerdo con cualquiera de las reivindicaciones 1 a 4, que comprende uno o más potenciadores de la permeación seleccionados entre dietilenglicol monoetiléter, un alcohol de ácido graso, un glicol, un disolvente aprótico o cualquier combinación de los mismos. Reivindicación 10: La composición de acuerdo con cualquiera de las reivindicaciones 5 a 9, en donde el dietilenglicol monoetiléter está presente en una cantidad del 3 al 40% p/p de la composición total. Reivindicación 12: La composición de acuerdo con cualquiera de las reivindicaciones anteriores, en donde la composición comprende además un antioxidante. Reivindicación 16: La composición de acuerdo con cualquiera de las reivindicaciones 12 a 15, en donde el antioxidante está presente en la composición de aproximadamente el 0,01% a aproximadamente el 1,0% p/p de la composición total. Reivindicación 17: La composición de acuerdo con cualquiera de las reivindicaciones anteriores, en donde la composición comprende dietilenglicol monoetiléter, alcohol oleílico y un antioxidante soluble en aceite. Reivindicación 18: La composición de acuerdo con cualquiera de las reivindicaciones anteriores, en donde la composición comprende entre 0,005% p/p y 5% p/p (convenientemente entre 0,005% p/p y 3% p/p y más convenientemente entre 0,005% p/p y 0,15% p/p) del Compuesto A o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063131647P | 2020-12-29 | 2020-12-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR124526A1 true AR124526A1 (es) | 2023-04-05 |
Family
ID=79283242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210103688A AR124526A1 (es) | 2020-12-29 | 2021-12-28 | Composiciones farmacéuticas tópicas y métodos |
Country Status (8)
Country | Link |
---|---|
US (1) | US20240092778A1 (es) |
CN (1) | CN116782883A (es) |
AR (1) | AR124526A1 (es) |
AU (1) | AU2021415273A1 (es) |
CA (1) | CA3204701A1 (es) |
IL (1) | IL303818A (es) |
TW (1) | TW202239410A (es) |
WO (1) | WO2022144758A1 (es) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
-
2021
- 2021-12-28 CA CA3204701A patent/CA3204701A1/en active Pending
- 2021-12-28 AU AU2021415273A patent/AU2021415273A1/en active Pending
- 2021-12-28 WO PCT/IB2021/062364 patent/WO2022144758A1/en active Application Filing
- 2021-12-28 US US18/266,974 patent/US20240092778A1/en active Pending
- 2021-12-28 IL IL303818A patent/IL303818A/en unknown
- 2021-12-28 AR ARP210103688A patent/AR124526A1/es unknown
- 2021-12-28 TW TW110149073A patent/TW202239410A/zh unknown
- 2021-12-28 CN CN202180087896.XA patent/CN116782883A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240092778A1 (en) | 2024-03-21 |
WO2022144758A1 (en) | 2022-07-07 |
TW202239410A (zh) | 2022-10-16 |
IL303818A (en) | 2023-08-01 |
CN116782883A (zh) | 2023-09-19 |
AU2021415273A1 (en) | 2023-06-29 |
CA3204701A1 (en) | 2022-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021002296A1 (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
AR114353A1 (es) | Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
EA018545B1 (ru) | Терапевтические композиции | |
RU2012140955A (ru) | Фармацевтические композиции спиро- оксиндолового соединения для местного введения и их применение в качестве терапевтических агентов | |
AR115283A1 (es) | Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílicoe | |
UY39032A (es) | Compuestos heterocíclicos como agentes antivirales | |
RU2011111206A (ru) | Композиции для местного применения, содержащие комбинацию по меньшей мере двух агентов, усиливающих проникновение | |
PH12017500136A1 (en) | Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof | |
CO2021007328A2 (es) | Mezclas y composiciones que comprenden 5-fluoro-4-imino-3-metil-1-tosil-3,4-dihidropirimidin-2-ona, y métodos de uso de los mismos | |
AR057067A1 (es) | Procedimiento para preparar sales de tiotropio, sales de tiotropio como tales y composiciones farmaceuticas de las mismas | |
AR078785A1 (es) | Formulaciones de bazedoxifeno con antioxidantes | |
RU2007139316A (ru) | Местные композиции антибиотиков бориновой кислоты и способы их использования | |
AR124526A1 (es) | Composiciones farmacéuticas tópicas y métodos | |
DOP2024000041A (es) | Compuestos espirocíclicos | |
ECSP22027287A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
UY38614A (es) | Derivados de benzodiazepinas como inhibidores del rsv | |
ES2648190T3 (es) | Compuestos para su uso en el tratamiento de la filariasis | |
AR115921A1 (es) | Ácido isolitocólico o ácido isoalolitocólico y derivados deuterados de los mismos para prevenir y tratar enfermedades asociadas a clostridium difficile | |
AR128066A1 (es) | Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos | |
AR105691A1 (es) | Método, composición y conjunto de elementos para tratar la disfunción eréctil | |
ES2759874T3 (es) | 1,25-Dihidroxivitamina D2 estabilizada y método de preparación de la misma | |
UY39625A (es) | Derivados tricíclicos útiles como inhibidores de parp7 | |
BR112022011284A2 (pt) | Composição tópica e métodos de medição da capacidade de resfriamento de uma composição tópica | |
RU2014122958A (ru) | Офтальмологическая композиция, обладающая противовоспалительным и противоаллергическим действием, для лечения конъюктивитов и блефаритов при местном применении | |
BR112023005443A2 (pt) | Derivado de y-carbolina fundido substituído heterocíclico, método de preparação do mesmo, intermediário do mesmo e uso do mesmo |